Abstract
REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
CNS & Neurological Disorders - Drug Targets
Title: REM Sleep Behavior Disorder and Narcolepsy
Volume: 8 Issue: 4
Author(s): Michel Billiard
Affiliation:
Keywords: Narcolepsy, REM sleep behavior disorder, Pathophysiology, Epidemiology, Clinical variants, Hypocretin/orexin
Abstract: REM (rapid eye movement) sleep behavior disorder (RBD) is a well known parasomnia [1]. Its first description in humans dates back to 1985, and its first description in narcoleptic patients to 1992. Although the precise pathophysiology of RBD remains unclear, it is likely, in the case of RBD associated with narcolepsy, that the altered function of hypocretin pathways projecting from the lateral hypothalamus to the ventrolateral part of the periaqueductal grey matter and the lateral pontine tegmentum has a consistent role. The percentage of narcoleptic patients complaining of clinical RBD lies somewhere between 10 and 15% of the narcoleptic population. The age of onset is younger than in the other forms of chronic RBD. Clinical features are the same as in the other forms of chronic RBD, but the frequency of the episodes is less marked. Associated features include other parasomnias, periodic limb movements in sleep (PLMs) and olfactory dysfunction. Polysomnographic tracings are remarkable for elevated submental electromyographic (EMG) tone and/or excessive phasic submental EMG twitching. Data on human leukocyte antigen (HLA) association and on cerebrospinal fluid (CSF) hypocretin/orexin levels are limited. Clinical variants include RBD induced or worsened by pharmacological agents, most of them being used to treat cataplexy, RBD in narcoleptic children and RBD in the context of symptomatic narcolepsy. Several treatments of RBD are available including clonazepam, melatonin and more recently pramipexole. However, in the absence of any pharmacological trials of these drugs on RBD in narcoleptic patients, it is difficult to provide guidance other than to recommend conventional treatments of RBD.
Export Options
About this article
Cite this article as:
Billiard Michel, REM Sleep Behavior Disorder and Narcolepsy, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921690
DOI https://dx.doi.org/10.2174/187152709788921690 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Nyctanthes arbor-tristis</i> Linn.: A Review on its Traditional Uses, Phytochemistry,
Pharmacological Activities, and Toxicity
Current Traditional Medicine Editorial [Hot Topic: Mechanisms of HIV-1 Latency Post HAART Treatment Area (Guest Editors: Lena Al-Harthi and Fatah Kashanchi)]
Current HIV Research Murine Skin-resident γδT Cells Impair the Immune Response to HSV in Skin
Infectious Disorders - Drug Targets Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry 123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Current Radiopharmaceuticals Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
Current HIV Research Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Antiviral Agents in the Prevention and Treatment of Virus-Induced Diabetes
Anti-Infective Agents in Medicinal Chemistry The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Manipulation of Dendritic Cells for Tumor Immunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry